Browse the evidence

GLP-1 receptor agonists (liraglutide, semaglutide) reduce body weight and improve metabolic parameters by modulating central appetite pathways and delaying gastric emptying.

GLP-1 drugs like semaglutide and liraglutide help you lose weight by reducing appetite and slowing digestion. They are taken daily or weekly. Gastrointestinal side effects are common initially but usually improve.

Tirzepatide treatment in individuals with obesity and prediabetes attenuates the decline in creatinine-cystatin C-based estimated glomerular filtration rate (eGFR) and reduces urine albumin-to-creatinine ratio (UACR) compared to placebo over 176 weeks.

If you have obesity and prediabetes, treatment with tirzepatide (a once-weekly injectable medication) has been shown to help protect your kidney function over a 3-year period compared to placebo. This protection is seen as a slower decline in kidney filtration rates and a reduction in albumin in the urine, even if your kidney function is currently normal. This suggests that early intervention with this medication may offer long-term organ protection beyond just weight loss.

SGLT2 inhibitors (dapagliflozin, empagliflozin, ipragliflozin) significantly reduce body weight in older adults with type 2 diabetes primarily through substantial fat mass loss, while causing only a modest, likely non-clinically meaningful reduction in skeletal muscle mass.

If you are an older adult with Type 2 Diabetes, SGLT2 inhibitors (like Jardiance or Farxiga) are effective for weight loss. Expect significant fat loss. You may lose a small amount of muscle, but it is not the primary driver of weight loss and is likely not clinically concerning for most. Monitor your strength if you are already frail, but the metabolic benefits of fat loss generally outweigh the modest muscle loss.

Tirzepatide (all doses) provides statistically greater improvements in triglycerides and diastolic blood pressure compared to Liraglutide, and generally comparable improvements in other cardiometabolic parameters compared to Semaglutide.

Tirzepatide not only aids weight loss but also offers statistically greater improvements in triglycerides and diastolic blood pressure compared to Liraglutide, with generally comparable benefits to Semaglutide for other heart health markers.

Bariatric surgery still outperforms pharmacotherapy in terms of absolute weight loss magnitude and durability, with surgery yielding approximately five times more weight loss in real-world cohorts.

While incretin drugs are powerful, bariatric surgery still achieves greater weight loss on average (25-35% vs 15-22%). If your goal is maximum possible weight loss and you are a surgical candidate, surgery may still be the most effective option. However, if you fear surgery or have contraindications, polyagonists offer a highly effective, non-surgical path to significant weight loss.

GLP-1 receptor agonists provide additive kidney benefits when used in combination with SGLT2 inhibitors, addressing residual cardiorenal risk.

If you are already taking an SGLT2 inhibitor for your kidney and heart health, ask your doctor if adding a GLP-1 receptor agonist could provide additional protection. These medications work through different mechanisms and can offer additive benefits, especially if you still have residual risk factors like high blood pressure or albuminuria.

Metabolic bariatric surgery (MBS) is more cost-effective than continuous GLP-1 pharmacotherapy, saving an average of $11,689 per patient over 2 years, while providing a definitive metabolic reset.

Bariatric surgery (like sleeve gastrectomy or gastric bypass) is not just a weight loss tool but a metabolic reset. While it has higher upfront costs, long-term data suggests it saves money compared to staying on GLP-1 medications indefinitely, as drug costs remain high while surgical maintenance costs drop. It works by altering your gut hormones to reduce hunger and improve insulin sensitivity.

Incretin therapies (semaglutide, tirzepatide) achieve MASH resolution and fibrosis improvement primarily through substantial, dose-dependent weight loss.

Semaglutide (2.4 mg weekly) and tirzepatide are weekly injections that reduce liver fat and inflammation by driving significant weight loss. They are highly effective for MASH resolution.

Emerging weight-lowering drugs (GLP-1/GIP/Glucagon agonists, amylin analogues, activin receptor antagonists) reduce cardiovascular risk factors (blood pressure, lipids, inflammation) and major adverse cardiovascular events (MACE) in obese patients, with some effects being independent of weight loss.

If you are obese and have cardiovascular risk factors, emerging drugs like semaglutide and tirzepatide offer significant benefits beyond just weight loss, including reduced risk of heart attacks and strokes. These benefits may come from direct effects on blood vessels and inflammation, not just weight loss. While side effects like nausea are common, they can often be managed. Oral options are becoming available, reducing the need for injections. These drugs are most effective when combined with lifestyle changes, but they can provide substantial help where lifestyle alone has failed.

Combining gut hormone analog medications (e.g., GLP-1/GIP agonists) with naltrexone-bupropion extended-release (NB-ER) provides a mechanistic rationale for improved weight loss in patients who fail to achieve goals with monotherapy, by targeting distinct satiety and reward pathways.

If you are taking a GLP-1 medication (like semaglutide or tirzepatide) and hitting a plateau or struggling with food cravings despite following the dose, ask your doctor about adding NB-ER (naltrexone-bupropion). This combination targets both physical fullness and the brain's reward system, which may help you lose more weight than the single medication alone.

Gut hormone analog medications (liraglutide, semaglutide, tirzepatide) reduce energy intake and alter food preferences primarily through delayed gastric emptying and hypothalamic/brainstem satiety signaling, rather than direct effects on reward centers.

GLP-1 medications like semaglutide work mainly by slowing digestion and signaling fullness to the brain, leading to significant weight loss (up to 21% for tirzepatide). While they may help with cravings, this is likely a secondary effect of weight loss rather than a direct 'craving blocker' action.

NB-ER (naltrexone-bupropion extended-release) reduces food cravings and improves control over eating by acting on central hypothalamic and mesolimbic dopaminergic systems, distinct from the peripheral effects of gut hormone analogs.

NB-ER helps with weight loss by targeting the brain's reward system to reduce cravings and improve self-control, rather than just slowing digestion. It typically leads to 6-12% weight loss over a year, depending on whether you have diabetes.

Tirzepatide is associated with significantly greater lean body mass (LBM) loss compared to semaglutide during routine care, with excess relative LBM losses of 1.1% to 2.0% at 3, 6, 9, and 12 months respectively.

If you are taking tirzepatide, expect to lose more lean muscle mass than if you were taking semaglutide for the same amount of weight loss. This effect increases with higher doses and longer duration. To counteract this, prioritize resistance training and adequate protein intake, and monitor your body composition, not just scale weight.

Patients with baseline musculoskeletal pain (cervicalgia, knee pain) experience significantly greater lean body mass loss during GLP-1 therapy, suggesting mobility limitations exacerbate muscle catabolism.

If you have joint pain, you are at higher risk for losing muscle while losing weight on GLP-1s. This is because pain limits your movement. Try to maintain some level of gentle activity or resistance training that does not aggravate your pain to protect your muscle mass.

Initiating Type 2 Diabetes screening at age 30 is recommended for asymptomatic individuals in the UAE, which is earlier than the standard age of 35, to address the region's high prevalence of prediabetes and diabetes.

If you live in the UAE and are 30 or older, get your blood sugar checked even if you feel healthy. This is not optional; it is the standard of care because diabetes is common and often silent. Early detection lets you fix it before it damages your heart or kidneys.

Individuals with Type 2 Diabetes should undergo annual screening for Cardio-Renal-Metabolic (CRM) risk, including blood pressure, lipid profile, and kidney function, to identify and manage multi-organ dysfunction early.

Once you have diabetes, you need a full health check-up every year, not just a blood sugar test. This includes checking your blood pressure, cholesterol, and kidney function. This annual check is your best defense against heart disease and kidney failure.

Individuals with Type 2 Diabetes should be screened for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) using the FIB-4 index, as nearly 70% of T2D patients are affected.

If you have diabetes, ask your doctor to check your liver health using a simple calculation called FIB-4. This test uses your age and blood results to estimate liver scarring risk. Since 70% of people with diabetes have some degree of liver fat, this check is essential for your overall health.

Incretin therapies reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with T2DM and/or established cardiovascular disease, independent of glycemic control.

If you have heart disease or high risk, these drugs offer significant protection against heart attacks and death, separate from weight loss. This benefit is a key factor in their clinical value and reimbursement decisions.

Current clinical guidelines recommend individualized perioperative management for GLP-1 RA users, with recent consensus shifting from mandatory discontinuation to risk-based assessment based on gastrointestinal symptoms and treatment duration.

Do not stop your GLP-1 medication on your own before surgery. Recent guidelines say you should likely keep taking it unless you have severe nausea or vomiting. Your surgical team will create a specific plan for you, possibly adjusting your fasting rules, to keep your blood sugar stable while minimizing lung risks.

Combining CPAP therapy with weight loss (via pharmacotherapy or lifestyle) yields greater improvements in cardiovascular risk markers than treating either condition alone.

If you have sleep apnea and are overweight, don't just focus on one. Using CPAP while also working to lose weight (through diet, exercise, or medication) provides the best protection for your heart and blood pressure. Treating just one condition leaves you at higher risk.

Next-generation incretin-based therapies (GLP-1 and GLP-1/GIP receptor agonists) significantly reduce systolic blood pressure, with the majority of this effect mediated by weight loss, though direct tissue-specific mechanisms also contribute.

If you have high blood pressure and obesity or type 2 diabetes, GLP-1 based medications like semaglutide or tirzepatide can significantly lower your blood pressure. Most of this benefit comes from the weight loss these drugs cause, but they also have direct positive effects on your blood vessels and kidneys. While they are more expensive than standard blood pressure pills, they offer broader cardiovascular protection. Discuss with your doctor if you are a candidate, especially if you have resistant hypertension or high cardiovascular risk.

After 6 months of semaglutide treatment, participants showed significant reductions in Psoriasis Area and Severity Index (PASI) by 48%, body mass index (BMI), and preperitoneal and superficial fat.

Semaglutide may be an effective treatment for improving psoriasis severity in obese patients.

Semaglutide treatment is associated with improvements in quality of life (DLQI) and depressive symptoms (BDI) after 6 months.

Improving psoriasis treatment may also enhance mental health and quality of life.

Emerging evidence suggests that combining IF and KD may offer synergistic metabolic effects.

Practitioners may explore the combination of IF and KD for enhanced metabolic benefits in patients.